Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
159
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

The Treatment Based on Ruxolitinib and Amphotericin B is Effective for Relapsed Leishmaniasis-Related Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review

Tingting CuiDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaView further author information
,
Jingshi WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaView further author information
&
Zhao WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 6625-6629 | Received 16 Aug 2022, Accepted 19 Oct 2022, Published online: 11 Nov 2022

References

  • Guo F, Kang L, Xu M. A case of pediatric visceral leishmaniasis-related hemophagocytic lymphohistiocytosis diagnosed by mNGS. Int J Infect Dis. 2020;97:27–29. doi:10.1016/j.ijid.2020.05.056
  • Galletta F, Cucinotta U, Marseglia L, et al. Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy. J Clin Pharm Ther. 2022;47(9):1478–1481. doi:10.1111/jcpt.13733
  • Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630–e637. doi:10.1016/S2352-3026(19)30156-5
  • Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–1675. doi:10.1182/blood-2015-12-684399
  • de Araujo FF, Costa-Silva MF, Pereira AAS, et al. Chemokines in Leishmaniasis: map of cell movements highlights the landscape of infection and pathogenesis. Cytokine. 2020;147:155339. doi:10.1016/j.cyto.2020.155339
  • La Rosee P. Alleviating the storm: ruxolitinib in HLH. Blood. 2016;127(13):1626–1627. doi:10.1182/blood-2016-02-697151
  • Yildiz H, Van Den Neste E, Defour JP, Danse E, Yombi JC. Adult haemophagocytic lymphohistiocytosis: a Review. QJM. 2020. doi:10.1093/qjmed/hcaa011
  • Trottestam H, Horne A, Arico M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–4584. doi:10.1182/blood-2011-06-356261
  • Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210–e212. doi:10.3324/haematol.2019.222471
  • Boonstra PS, Ahmed A, Merrill SA, Wilcox RA. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis. Am J Hematol. 2021;96(4):E103–E105. doi:10.1002/ajh.26091
  • Wang J, Zhang R, Wu X, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, Phase 2 trial. Br J Haematol. 2021;193(4):761–768. doi:10.1111/bjh.17331
  • Yildiz H, Bailly S, Van Den Neste E, Yombi JC. Clinical management of relapsed/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag. 2021;17:293–304. doi:10.2147/TCRM.S195538
  • Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering committee of the histiocyte society. J Allergy Clin Immunol Pract. 2018;6(5):1508–1517. doi:10.1016/j.jaip.2018.05.031
  • Zheng C, Wang L, Li Y, Zhou XN. Visceral leishmaniasis in northwest China from 2004 to 2018: a spatio-temporal analysis. Infect Dis Poverty. 2020;9(1):165. doi:10.1186/s40249-020-00782-4
  • Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011;208(6):1203–1214. doi:10.1084/jem.20102538
  • Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004;71(5):561–567. doi:10.4269/ajtmh.2004.71.561
  • Gautam S, Kumar R, Maurya R, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis. 2011;204(7):1134–1137. doi:10.1093/infdis/jir461
  • Dos Santos PL, de Oliveira FA, Santos ML, et al. The severity of visceral leishmaniasis correlates with elevated levels of serum IL-6, IL-27 and sCD14. PLoS Negl Trop Dis. 2016;10(1):e0004375. doi:10.1371/journal.pntd.0004375
  • Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:614704. doi:10.3389/fimmu.2021.614704
  • Kumar R, Bunn PT, Singh SS, et al. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep. 2020;30(8):2512–2525 e2519. doi:10.1016/j.celrep.2020.01.099
  • Diamantidis MD, Palioura A, Ioannou M, Tsangalas E, Karakousis K Sr. Hemophagocytic lymphohistiocytosis as a manifestation of underlying visceral leishmaniasis. Cureus. 2020;12(12):e11911. doi:10.7759/cureus.11911
  • Shi Q, Huang M, Li X, et al. Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection. PLoS Negl Trop Dis. 2021;15(11):e0009944. doi:10.1371/journal.pntd.0009944

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.